Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 13/20 | 0.57 |
| ▸ | GIPR | P48546 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.48 |
| ▸ | MAT2A | P31153 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642765 | 0.84 | PLA2G10 (0.52) | GCGRGIPRKCNH2PLA2G10MAT2A | |
| SCHEMBL2643993 | 0.84 | GCGR (0.52) | GCGRGIPRKCNH2PLA2G10MAT2A | |
| SCHEMBL2643861 | 0.83 | GCGR (0.56) | GCGRGIPRKCNH2PLA2G10MAT2A | |
| SCHEMBL2643230 | 0.83 | GCGR (0.55) | GCGRGIPRKCNH2PLA2G10MAT2A | |
| SCHEMBL2643736 | 0.81 | GCGR (0.51) | GCGRGIPRKCNH2PLA2G10MAT2A | |
| SCHEMBL2643458 | 0.79 | GCGR (0.54) | GCGRGIPRKCNH2PLA2G10MAT2A | |
| SCHEMBL718533 | 0.75 | RXFP1 (0.52) | — | |
| SCHEMBL719164 | 0.74 | GCGR (0.55) | GCGRGIPRKCNH2MAT2AMAPT | |
| SCHEMBL2662074 | 0.74 | GCGR (1.00) | GCGRGIPRKCNH2 | |
| SCHEMBL928245 | 0.74 | GCGR (1.00) | GCGRGIPRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-7598398-B2 | Acyl indoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCGR 90/4885GIPR 41/4885KCNH2 2392/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCGR 90/4885GIPR 41/4885KCNH2 2392/4885 |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | GPR119, IAPP, GLP1R | GCGR 6/4885GIPR 4/4885KCNH2 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.